IRIDEX Corporation (IRIX)
| Bid | 1.13 |
| Market Cap | 19.79M |
| Revenue (ttm) | 48.67M |
| Net Income (ttm) | -8.91M |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -2.18 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.21 |
| Volume | 72,064 |
| Avg. Volume (20D) | 94,389.4 |
| Open | 1.21 |
| Previous Close | 1.19 |
| Day's Range | 1.13 - 1.24 |
| 52-Week Range | 0.78 - 3.25 |
| Beta | 0.74 |
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuL...
Analyst Forecast
According to 1 analyst ratings, the average rating for IRIX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 69.68% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
IRIDEX Corporation (IRIX) Strategic Vision Conference Call (Transcript)IRIDEX Corporation (NASDAQ:IRIX ) Strategic Vision Conference Call April 16, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Patrick Mercer - Chief Executive Officer Will Moore -...
